Arthritis Drugs Could Treat Persistent COVID Lung Complications
New research suggests that existing FDA-approved medications may help treat lingering lung complications caused by COVID-19 by disrupting harmful immune responses.
New research suggests that existing FDA-approved medications may help treat lingering lung complications caused by COVID-19 by disrupting harmful immune responses.
New research suggests that existing FDA-approved medications may help treat lingering lung complications caused by COVID-19 by disrupting harmful immune responses.
Read MoreTwo practice parameters from the Joint Task Force for Practice Parameters offer evidence-based recommendations for the diagnosis and management of anaphylaxis and atopic dermatitis in pediatric and adult patients.Â
Read MoreThe FDA approved Olumiant (baricitinib) for hospitalized adults with COVID-19 requiring supplemental oxygen, noninvasive or invasive mechanical ventilation, or ECMO.
Read MoreThe NIH updated its COVID-19 Treatment Guidelines with new information following the FDA emergency use authorization of baricitinib.
Read MoreThe combination of baricitinib, an anti-inflammatory drug, and remdesivir reduced time to recovery for people hospitalized with COVID-19.
Read MoreThe rheumatoid arthritis drug baricitinib can block viral entry and reduce mortality in patients with moderate to severe COVID-19, according to translational research by scientists from Karolinska Institutet in Sweden.
Read MoreThe NIAID is enrolling participants in its ACTT-4 clinical trial to assess the effectiveness of dexamethasone plus remdesivir, compared to baricitinib plus remdesivir.
Read MoreThe FDA issued an EUA for the drug baricitinib in combination with remdesivir to treat patients age two and older who are hospitalized COVID-19.
Read More